Embecta (NASDAQ:EMBC - Get Free Report) announced its quarterly earnings data on Friday. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.04, RTT News reports. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. The business had revenue of $259.00 million during the quarter, compared to the consensus estimate of $261.77 million. During the same quarter in the prior year, the firm earned $0.67 EPS. The company's revenue for the quarter was down 9.8% compared to the same quarter last year. Embecta updated its FY 2025 guidance to 2.700-2.900 EPS.
Embecta Price Performance
Embecta stock traded down $0.02 during midday trading on Thursday, reaching $11.57. The stock had a trading volume of 53,088 shares, compared to its average volume of 448,120. The firm's fifty day simple moving average is $12.41 and its two-hundred day simple moving average is $15.70. Embecta has a twelve month low of $10.83 and a twelve month high of $21.48. The firm has a market cap of $672.61 million, a price-to-earnings ratio of 11.53, a PEG ratio of 0.78 and a beta of 1.24.
Embecta Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Wednesday, May 28th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 5.19%. The ex-dividend date of this dividend is Wednesday, May 28th. Embecta's dividend payout ratio is 66.67%.
Analyst Upgrades and Downgrades
Separately, Mizuho started coverage on shares of Embecta in a report on Thursday, April 10th. They issued a "neutral" rating and a $15.00 price objective for the company.
Check Out Our Latest Research Report on Embecta
About Embecta
(
Get Free Report)
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Recommended Stories
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
